Buzzard Pharmaceuticals is a biopharmaceutical development company. We are developing Isunakinra, an IL-1 inhibitor for the treatment of cancer. Isunakinra (EBI-005) is a recombinant protein binding to the IL1R1 with high potency. IL-1 mediates the recruitment of immunesuppressive myeloid cells (PMN-MDSCs, neutrophils and T2 macrophages) to the tumor - that inhibit CD8 T cells from entering the tumor and killing tumor cells. Moreover, IL-1 stimulates angiogensis and tumor spread.